Cryosite Limited (ASX:CTE)

Australia · Delayed Price · Currency is AUD

1.200

0.00 (0.00%)

Jul 21, 2026, 4:10 PM AEST

69.01% (1Y)

Market Cap	58.57M +69.0%
Revenue (ttm)	15.75M +22.6%
Net Income	2.18M +19.2%
EPS	0.04 +14.4%
Shares Out	48.81M
PE Ratio	27.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,312
Open	1.310
Previous Close	1.200
Day's Range	1.200 - 1.310
52-Week Range	0.660 - 1.310
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 10, 2026

About Cryosite

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell ... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1999

Employees 25

Stock Exchange Australian Securities Exchange

Ticker Symbol CTE

Full Company Profile

Financial Performance

In fiscal year 2025, Cryosite's revenue was 14.12 million, an increase of 11.93% compared to the previous year's 12.61 million. Earnings were 1.88 million, an increase of 2.39%.

Financial Statements